Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Erdoğan declares state of emergency in Turkey after deadly earthquake
    • Iran’s ‘ghost fleet’ switches into Russian oil
    • Joe Biden to revive plan for billionaire tax in State of the Union address
    • Fed chair warns of even higher rates if jobs data stays strong
    • Chinese spy balloon incursion reveals past US intelligence failings
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Ammunition supply chain crisis: Ukraine war tests Europe in race to rearm
      • BP slows oil and gas retreat after record $28bn profit
      • Gautam Adani’s ports business to repay $600mn in race to cut debt
      • Singapore’s GIC cuts exposure to H2O Asset Management
      • Jupiter dumps Starling Bank and rules out unlisted stocks
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news updates from February 7: Ukraine’s allies to send up to 178 tanks, Sunak reshuffles cabinet
      • Iran’s ‘ghost fleet’ switches into Russian oil
      • Russia’s budget deficit soars as energy revenues slump by almost half
      • BP slows oil and gas retreat after record $28bn profit
      • Jupiter dumps Starling Bank and rules out unlisted stocks
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Brexit could be reversed — here’s how
      • Are CEOs with MBAs good for business?
      • Lessons from the great reflation
      • We should all be asking more questions
      • A Republican-led US would not shrink from the world
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Barclays chief: the life lessons I have discovered during cancer treatment
      • Management research: why are so few of its ideas taken up?
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • How to ski, shop, sled and sip it in St Moritz
      • American Resistance by David Rothkopf — managing the Trump horror show
      • Hogwarts Legacy review — 1890s-set prequel is a step forward for Harry Potter
      • Ask Adeela: what to do about dark spots and pigmentation?
      • How long would you wait for a steak?
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Merck & Co Inc

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Friday, 23 December, 2022
      LexDrugs research
      Medicines: triumph of science in 2022 is worth celebrating Premium content

      From obesity drugs to cancer treatments, this year should be remembered for pharmaceutical advances

    • Thursday, 22 December, 2022
      Coronavirus treatment
      Merck antiviral trial shows promising impact on Covid recovery time

      Results of UK study show drug cuts symptom duration by about 4 days but does not reduce deaths

    • Tuesday, 13 December, 2022
      Drugs research
      Moderna’s mRNA cancer vaccine shows promise in early trial

      Study suggests combination with Merck immunotherapy drug reduces risk of death in high-risk patients

    • Thursday, 6 October, 2022
      Coronavirus treatment
      Merck Covid antiviral pill did not cut hospitalisation risk, study finds

      UK trial shows ‘no difference’ between taking molnupiravir or placebo in reducing clinical admissions during Omicron wave

    • Sunday, 7 August, 2022
      Pharmaceuticals sector
      Merck defends tax approach against senator’s claims of avoidance

      Chief financial officer says drugmaker complies with law amid congressional probe

    • Friday, 8 July, 2022
      Lex
      Merck/SeaGen: regulatory hurdles will be tough to clear Premium content

      Tie-up faces obstacles in current climate of aggressive watchdogs and concern over drug prices

    • Thursday, 7 July, 2022
      Pharmaceuticals sector
      Merck in talks over $40bn deal for cancer biotech SeaGen

      US group attracted by approved drugs as it prepares to lose patent protection of Keytruda

    • Wednesday, 16 February, 2022
      Coronavirus treatment
      Merck struggles to win European approval for Covid antiviral pill

      EMA said to be unlikely to grant marketing authorisation to molnupiravir this month after ‘problematic’ data

    • Wednesday, 22 December, 2021
      Covid-19 vaccines
      France cancels order for Merck antiviral tablet on efficacy fears

      Concerns grow over molnupiravir’s ability to reduce Covid hospitalisations and deaths

    • Sunday, 5 December, 2021
      Coronavirus treatment
      Merck takes aim at Pfizer’s Covid pill as concerns linger over its own drug

      Executive says patients on other medications will not be able to take competing antiviral treatment

    • Tuesday, 30 November, 2021
      Coronavirus treatment
      Merck’s Covid pill secures narrow backing from US regulatory panel

      Experts advising FDA recommend treatment for high-risk patients amid fears over Omicron variant

    • Friday, 26 November, 2021
      Coronavirus treatment
      Merck says its Covid antiviral treatment less effective than first thought

      Full analysis of trial results shows molnupiravir had a risk reduction of 30%

    • Friday, 12 November, 2021
      The Big Read
      The Covid drugs are finally here

      New medicines from Pfizer and Merck could take some pressure off hospitals. But will they work on the already vaccinated?

    • Thursday, 4 November, 2021
      Coronavirus treatment
      Merck’s Covid pill Lagevrio secures green light from UK regulator

      First authorisation for antiviral drug that halves risk of hospitalisation or death

    • Wednesday, 27 October, 2021
      Coronavirus treatment
      Merck signs royalty-free deal to expand access to its Covid-19 pill

      Move contrasts with mRNA makers Pfizer and Moderna, which have rejected sharing vaccine technology

    • Tuesday, 12 October, 2021
      LexCoronavirus treatment
      Coronavirus pill: Merck forges a new hammer to crack pandemic Premium content

      Molnupiravir has limitations but drugmakers should be able to build on it to create other treatments

    • Tuesday, 12 October, 2021
      Coronavirus treatment
      Merck aims to double supply of Covid-19 antiviral pill on rising demand

      Drugmaker seeks authorisation from FDA for oral treatment shown to prevent severe disease in vulnerable people

    • Wednesday, 6 October, 2021
      News in-depthPharmaceuticals sector
      Merck on deals hunt as patent cliff looms for top cancer drug

      Investors fret over how company will fare when Keytruda loses exclusivity

    • Friday, 1 October, 2021
      Coronavirus treatment
      Merck says Covid antiviral pill halves risk of hospitalisation and death

      US pharma group seeks authorisation for first drug of its kind after ‘remarkable’ clinical trial

    • Thursday, 30 September, 2021
      Merck to buy Acceleron Pharma for $11.5bn

      Acquisition will expand US pharmaceutical company’s pipeline of cardiovascular treatments

    • Thursday, 3 June, 2021
      Medical science
      AstraZeneca and Merck point to progress in fighting breast cancer

      Lynparza shown to reduce recurrence rates, while Novartis to unveil new type of radiotherapy

    • Wednesday, 10 March, 2021
      News in-depthFT Film24 min
      Covid-19 and the business of vaccines

      New vaccine producers and mRNA technology are shaking up the market

    • Tuesday, 2 March, 2021
      Covid-19 vaccines
      Biden says US will have enough jabs to vaccinate all adults by end of May

      White House announces accelerated timeline after brokering production deal between J&J and Merck

    • Friday, 26 February, 2021
      UK business & economy
      Cancer drug is first to begin fast-track UK approval process

      Approach seeks to cut years off traditional licensing process for treatments

    • Tuesday, 16 February, 2021
      News in-depthCovid-19 vaccines
      Why the three biggest vaccine makers failed on Covid-19

      GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In